Effects of Prior Influenza Exposure on Immunogenicity of Influenza Vaccine.

cross-reactivity seasonal influenza vaccine

Journal

Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 06 01 2020
accepted: 22 05 2020
entrez: 21 8 2020
pubmed: 21 8 2020
medline: 21 8 2020
Statut: epublish

Résumé

In this study, we investigated the effects of prior influenza exposure on vaccine-elicited humor immune responses to circulating influenza variants. We randomly selected 360 participants in previous clinical trials stratified by age. Blood samples were collected and tested by hemagglutination-inhibition tests during the 2015-2016 influenza seasons in China. The antigenic map was plotted and antigenic distance was calculated. Subjects with H1-priming had higher cross-reactive antibodies titers against A/JiangsuTinghu/11019/2015(H3N2) compared with subjects with B-priming did ( Our results suggest that prior exposure to H1 or B influenza virus may influence cross-reactivity of H3-specific postvaccination responses and consequently could influence the vaccine effectiveness. Our findings also support that there are age-specific differences in human postvaccination responses.

Sections du résumé

BACKGROUND BACKGROUND
In this study, we investigated the effects of prior influenza exposure on vaccine-elicited humor immune responses to circulating influenza variants.
METHOD METHODS
We randomly selected 360 participants in previous clinical trials stratified by age. Blood samples were collected and tested by hemagglutination-inhibition tests during the 2015-2016 influenza seasons in China. The antigenic map was plotted and antigenic distance was calculated.
RESULTS RESULTS
Subjects with H1-priming had higher cross-reactive antibodies titers against A/JiangsuTinghu/11019/2015(H3N2) compared with subjects with B-priming did (
CONCLUSIONS CONCLUSIONS
Our results suggest that prior exposure to H1 or B influenza virus may influence cross-reactivity of H3-specific postvaccination responses and consequently could influence the vaccine effectiveness. Our findings also support that there are age-specific differences in human postvaccination responses.

Identifiants

pubmed: 32818136
doi: 10.1093/ofid/ofaa181
pii: ofaa181
pmc: PMC7423295
doi:

Types de publication

Journal Article

Langues

eng

Pagination

ofaa181

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Références

Vaccines (Basel). 2018 May 21;6(2):
pubmed: 29883414
Vaccine. 2016 Feb 10;34(7):981-8
pubmed: 26813801
Viruses. 2019 Jan 30;11(2):
pubmed: 30704019
J Immunol. 2009 Sep 1;183(5):3294-301
pubmed: 19648276
Protein Eng Des Sel. 2011 Mar;24(3):291-9
pubmed: 21123189
NPJ Vaccines. 2019 Jul 9;4:28
pubmed: 31312528
Clin Infect Dis. 2014 Nov 15;59(10):1375-85
pubmed: 25270645
Virus Res. 2015 Jun 2;204:40-6
pubmed: 25892718
Clin Infect Dis. 2016 Jul 1;63(1):21-32
pubmed: 27025838
Clin Infect Dis. 2017 Jul 15;65(2):259-267
pubmed: 28369230
BMC Med. 2013 Jun 25;11:153
pubmed: 23800265
Expert Rev Vaccines. 2017 Nov;16(11):1155-1169
pubmed: 28870140
J Infect Dis. 2009 Jan 15;199(2):159-67
pubmed: 19086915
Science. 2014 Nov 21;346(6212):996-1000
pubmed: 25414313
Antiviral Res. 2015 Feb;114:106-12
pubmed: 25513756
Emerg Infect Dis. 2010 Jun;16(6):1023-4
pubmed: 20507764
Medicine (Baltimore). 2018 Jul;97(29):e11551
pubmed: 30024549
Clin Infect Dis. 2018 Oct 30;67(10):1523-1532
pubmed: 29672713
Expert Rev Vaccines. 2017 Jul;16(7):1-14
pubmed: 28562111
Bull World Health Organ. 1987;65(2):181-7
pubmed: 3496984
Clin Infect Dis. 2014 Feb;58(3):319-27
pubmed: 24235265
PLoS One. 2014 Mar 25;9(3):e92153
pubmed: 24667168
J Clin Microbiol. 1999 Apr;37(4):937-43
pubmed: 10074505

Auteurs

Jia-Qian Cao (JQ)

School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

Peng-Fei Jin (PF)

Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu, People's Republic of China.

Jing-Xin Li (JX)

Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu, People's Republic of China.

Zhao-Zhun Zeng (ZZ)

School of Public Health, Southeast University, Nanjing, Jiangsu, People's Republic of China.

Li Zhang (L)

Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu, People's Republic of China.

Fan-Yue Meng (FY)

Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu, People's Republic of China.

Kai Chu (K)

Vaccine Clinical Evaluation Department, Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu, People's Republic of China.

Yuan-Yuan Wang (YY)

School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

Feng-Cai Zhu (FC)

School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Province Center for Disease Control and Prevention, Nanjing, Jiangsu, People's Republic of China.
Center for Global Health, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.

Classifications MeSH